高级搜索

卡培他滨治疗进展期三阴性乳腺癌疗效分析

高会全, 马学真, 朱 超, 董桂芝, 杜朝晖, 申文江

高会全, 马学真, 朱 超, 董桂芝, 杜朝晖, 申文江. 卡培他滨治疗进展期三阴性乳腺癌疗效分析[J]. 肿瘤防治研究, 2014, 41(04): 383-386. DOI: 10.3971/j.issn.1000-8578.2014.04.022
引用本文: 高会全, 马学真, 朱 超, 董桂芝, 杜朝晖, 申文江. 卡培他滨治疗进展期三阴性乳腺癌疗效分析[J]. 肿瘤防治研究, 2014, 41(04): 383-386. DOI: 10.3971/j.issn.1000-8578.2014.04.022
shu
GAO Huiquan, MA Xuezhen, ZHU Chao, DONG Guizhi, DU Zhaohui, SHEN Wenjiang. Retrospective Analysis of Capecitabine in Routine Treatment of Advanced Triple Negative-breast Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(04): 383-386. DOI: 10.3971/j.issn.1000-8578.2014.04.022
Citation: GAO Huiquan, MA Xuezhen, ZHU Chao, DONG Guizhi, DU Zhaohui, SHEN Wenjiang. Retrospective Analysis of Capecitabine in Routine Treatment of Advanced Triple Negative-breast Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(04): 383-386. DOI: 10.3971/j.issn.1000-8578.2014.04.022
shu

卡培他滨治疗进展期三阴性乳腺癌疗效分析

  • 1. 266021山东青岛，青岛大学医学院肿瘤学系；2.解放军第四零四医院肿瘤中心；3.青岛大学医学院附属二院肿瘤科；4.北京大学第一医院放疗科

详细信息
    作者简介:

    高会全（1978-），男，硕士在读，主治医师，主要从事肿瘤的综合治疗及研究

    通信作者:

    马学真，E-mail：maxuezhen1968@126.com

  • 中图分类号: R737.9

Retrospective Analysis of Capecitabine in Routine Treatment of Advanced Triple Negative-breast Carcinoma

  • 1.School of Medicine, Medical College, Qingdao University, Qingdao 266021, China; 2.Cancer central of PLA 404 Hospital; 3.The Second Affi liated Hospital to Medical College of Qingdao University; 4.Department of Radiation Oncology, Peking University First Hospital

摘要

    摘要
  • 摘要: 目的 观察卡培他滨在未经选择的进展期三阴性乳腺癌患者治疗中的疗效和不良反应。方法 收集青岛大学医学院附属二院肿瘤科采用卡培他滨单药或联合化疗的进展期三阴性乳腺癌病例45 例，回顾分析其近期疗效、无进展生存时间（PFS）和不良反应。结果 中位随访8月，所有患者总有效率为60%。卡培他滨联合用药组有效率66.7%，单药组有效率33.3%，两者比较差异有统计学意义（P=0.028）。所有患者中位PFS为7.75月。单药组和联合组中位PFS分别为9.25月和7.55月，差异无统计学意义（P=0.751）。基础体能状况是PFS的重要预测因素（P=0.005）。无复发间期是否大于2年（P=0.198）不是PFS的预测因素。主要不良反应为手足综合征、胃肠道反应及骨髓抑制。结论 卡培他滨治疗进展期三阴性乳腺癌具有较好的疗效，不良反应可耐受。日常临床实践中疗效与干预性临床试验结果相同。

     

    Abstract: Objective To observe the efficacy and adverse reaction of capecitabine in routine clinical practice for unselected advanced triple negative-breast cancer(TNBC). Methods Forty-five advanced TNBC patients with capecitabine monotherapy or combined chemotherapy were collected by The Second Affiliated Hospital to Medical College of Qingdao University. The short-term efficacy, progression-free survival(PFS), and adverse reaction were analyzed retrospectively. Results Overall response rate(ORR) was 60% after 8 months of median follow-up. Response rate of combined chemotherapy group and monotherapy group was 66.7% and 33.3% respectively(P=0.028). Good performance status at baseline was a signifi cant predictor of effi cacy(P=0.005). Relapse-free interval after surgery(P=0.198) was not signifi cant predictor of PFS. The most common toxicity was hand-foot syndrome, gastrointestinal reaction and myelosuppression. Conclusion Capecitabine is a feasible, effective and well tolerated treatment for advanced TNBC. The effi cacy in real-life clinical practice is as same as results from interventional studies.

     

    • HTML全文
    • 参考文献(12)
  • [1] Siedentopf F, Gohler T, Hesse T, et al. Capecitabine in the routine treatment of Advanced breast cancer：results from a noninterventional observational study in 876 patients[J]. Onkologie, 20 09,32(11):31-6.
    [2] Chu QD, King T, Hurd T. Triple-negative breast cancer[J].Int J Breast Cancer,2012,2012:671684.
    [3] de Ruijter TC, Veeck J, de Hoon JP, et al. Characteristics of triple-negative breast cancer[J]. J Cancer Res Clin Oncol,2011,137(2):183-92.
    [4] Niwińska A, Olszewski W, Murawska M, et al. Triple- negative breast cancer with brain metastases: a comparison between basallike and non-basal-like biological subtypes[J].J Neurooncol,2011, 10 5(3):547-53.
    [5] Liao LL. The therapy of breast cancer under the guidance of new type of molecular[N].Zhongguo Yi Xue Lun Tan Bao,2011-7-8 （B2） [廖莉莉.新分子分型指导下的乳腺癌治疗[N].中国医 学论坛报,2011-7-8（B2）.]
    [6] Meyer P, Landgraf K, Hogel B, et al. BRCA2 Mutations and Triple-Negative Breast Cancer[J]. PLoS One,2012,7(5):e38361.
    [7] Chu QD, Henderson AE, Ampil F, et al. Outcome for patients with triple-negative breast cancer is not dependent on race/ethnicity[J]. Int J Breast Cancer,2012,2012:764570.
    [8] Chen XS, Ma CD, Wu JY, et al. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer[J]. Tumori, 20 10,96(1):103-10.
    [9] Hameed H, Cassidy J. Use of capecitabine in management of early colon cancer[J]. Cancer Manag Res,2011,3:295-9.
    [10] Xie LB, Xie L, Yuan LF. Clinical observation of docetaxel combined with capecitabine in the treatment of anthracycline resistant triple-negative advanced breast cancer[J]. Zhonghua Ru Xian Bing Za Zhi(Dian Zi Ban),2010,4(3): 61-2. [谢联斌， 谢莉，袁丽方.多西紫杉醇联合卡培他滨治疗蒽环类耐药 晚期三阴性乳腺癌的临床观察[J].中华乳腺病杂志（电子 版） ,2010,4(3):61-2.]
    [11] Dong NN, Wang MY, Zhang Q. Analysis on clinical efficacy of gemcitabine combined with capecitabine for patients with anthracycline and taxane-refractory metastatic breast cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2010,37(1):88-90. [董宁宁, 王明玉, 张琼. 吉西 他滨联合卡培他滨治疗蒽环类和紫杉类药物耐药的转移性乳腺 癌临床疗效分析[J]. 肿瘤防治研究, 2010,37(1):88-90.]
    [12] Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant transtuzumab in the Finland Capecitabine Trial[J]. Acta Oncol,2014,53(2):186-94.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  2150
  • HTML全文浏览量:  417
  • PDF下载量:  2792
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-01-27
  • 修回日期:  2013-05-19
  • 刊出日期:  2014-04-24

目录

摘要
HTML全文
    参考文献(12)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：19054740 今日访问：28634

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭

    声明：谨防诈骗